Khairat Al HENNAWİ, R. Nalan TİFTİK, İsmail ÜN, Kansu BÜYÜKAFŞAR

The Role of Steroid Receptors in the Proliferation and Migration of Endometrial Adenocarcinoma HEC1A Cell Line

Objectives: Endometrial carcinoma is one of the most common gynecological cancers. It is generally divided into oestrogen-dependent type I, and oestrogen-independent type II. Although the expression of some steroid receptors has been documented in type II endometrial carcinoma, their roles in tumor progression have not been fully elucidated yet. Thus in this study, we aimed to examine the role of compounds acting on steroid receptors in type II, on HEC1A cultured cells. Methods: We tested the effect of mifepristone (the glucocorticoid and progesterone receptor blocker, 10-8M), bicalutamide (the androgen receptor blocker, 10-6M), G15 (the G-protein-coupled estrogen receptor-1 blocker, 10-7M) and PHTPP (2-Phenyl-3-(4-hydroxyphenyl)-5,7-bis (trifluoromethyl)-pyrazolo [1,5-a]pyrimidine, the estrogen receptor-β blocker, 10-7M), on proliferation. Proliferation was assessed by xCELLigence analysis system and migration was examined by using wound-healing model. Results: None of the drugs, at the used concentrations, have affected the proliferation of HEC1A cells. However, migration was significantly increased at the 24th and the 48th hour of mifepristone application (p<0.05, P<0.01, respectively). Bicalutamide also increased migration at the 24th hour (p<0.05). G15 and PHTPP did not change the migration of cells. Conclusions: These results suggest that, unlike other steroid receptors, glucocorticoid and/or progesterone receptors may play an important role in the reducing migration of endometrial carcinoma and might be used as targets to reduce the metastasis of this type of cancer.

Keywords:

Endometrial adenocarcinoma, steroid receptors, proliferation; migration,

PDF

___

1. Bray F, Colombet M, Mery L, et al. Cancer Incidence in Five Continents, Vol. XI. Lyon: IARC Publication;2018.
2.https://gco.iarc.fr/today/home. Source: Globocan 2020 (Turkey) Accessed April 19, 2023.
3.Felix AS, Weissfeld JL, Stone RA, et al. Factorsassociated with Type I and Type II endometrialcancer. Cancer Causes Control. 2010;1(11):1851-6.
4.Setiawan VW, Yang HP, Pike MC, et al. Type I andII Endometrial Cancers: Have They Different RiskFactors? J Clin Oncol. 2013;31(20):2607-18.
5.Gronemeyer H, Gustafsson JÅ, Laudet V. Principles for modulation of the nuclear receptor superfamily.Nat Rev Drug Discov. 2004;3(11):950-64.
6.Ahmad N, Kumar R. Steroid hormone receptors incancer development: A target for cancertherapeutics. Cancer Lett. 2011;1:300(1):1-9.
7.Shen F, Gao Y, Ding J, Chen Q. Is the positivity ofestrogen receptor or progesterone receptordifferent between type 1 and type 2 endometrialcancer? Oncotarget. 2017;3;8(1):506-11.
8.Zhang Y, Guo R, Ge X, Qiao Y. Effect of GPER on theactivation of PI3K/Akt induced by 17β-estradiol inendometrial carcinoma cells Zhonghua Fu Chan KeZa Zhi. 2012;47(4):292-6.
9.Hashimoto C, Miki Y, Tanaka S, et al. 17β-hydroxysteroid dehydrogenase type 2 expression isinduced by androgen signaling in endometrialcancer. Int J Mol Sci. 2018;10;19(4):1139.
10.Circirci Y, Tiftik RN, Un İ. Effect of the Wnt/β-catenin pathway inhibitors on cell proliferation andmig ration of HEC-1A endometrial adenocarcinoma:experimental cell culture model. Eur Res J.2021;7(3):218-24.
11.Li A, Felix JC, Minoo P, Amezcua CA, Jain JK. Effectof mifepristone on proliferation and apoptosis ofIshikawa endometrial adenocarcinoma cells. FertilSteril. 2005;84(1):202-11.
12.Sang L, Lu D, Zhang J, Du S, Zhao X. Mifepristoneinhibits proliferation, migration and invasion ofHUUA cells and promotes its apoptosis by regulation of FAK and PI3K/AKT signaling pathway. OncoTargets Ther. 2018;4:11:5441-49.
13.Ponikwicka-Tyszko D, Chrusciel M,Stelmaszewska J, et al. Molecular mechanismsunderlying mifepristone’s agonistic action onovarian cancer progression. EBioMedicine.2019;1:47:170-83.
14.Parker C, Castro E, Fizazi K, et al. Prostate cancer:ESMO Clinical Practice Guidelines for diagnosis,treatment and follow-up†. Ann Oncol.2020;31(9):1119-1134.
15.Li J, Xiang S, Zhang Q, et al. Combination ofcurcumin and bicalutamide enhanced the growthinhibition of androgen-independent prostate cancercells through SAPK/JNK and MEK/ERK1/2-mediated targeting NF-κB/p65 and MUC1-C. J ExpClin Cancer Res. 2015;15;34(1):46.
16.St John Floyd M, Teahan SJ, Fitzpatrick JM,Watson RWG. Differential mechanisms ofbicalutamide-induced apoptosis in prostate celllines. Prostate Cancer Prostatic Dis. 2009;12(1):25-33.
17.Mangerini R, Argellati F, Pfeffer U, Boccardo F.Effects of Bicalutamide and 4OH-Tamoxifen onAndrogen-regulated Gene Expression in the LNCaPCell Line. Anticancer Res. 2012;32(12):5323-9.
18.Boccardo F, Medicina D, Galmozzi F, Emionite L,Lo Casto M. 4-OH Tamoxifen does not Interfere withBicalutamide Inhibitory Effects on Human ProstaticCancer Cells In Vitro. Anticancer Res.2005;25(6B):4277-80.
19.Robinson JLL, MacArthur S, Ross-Innes CS, et al.Androgen receptor driven transcription inmolecular apocrine breast cancer is mediated byFoxA1. EMBO J. 2011;24;30(15):3019-27.
20.Kong Y, Qu F, Yuan X, Yan X, Yu W. Effect ofBicalutamide on the proliferation and invasion ofhuman triple negative breast cancer MDA-MB-231cells. Medicine (Baltimore). 2020;99(17):e19822.
21.Hao K, Zhao S, Cui D, et al. Androgen receptorantagonist bicalutamide induces autophagy andapoptosis via ULK2 upregulation in human bladdercancer cells. Int J Clin Exp Pathol.2017;1:10(7):7603-15.
22.Liu B, Zhou M, Li X, et al. Interrogation of genderdisparity uncovers androgen receptor as thetranscriptional activator for oncogenic miR-125b ingastric cancer. Cell Death Dis. 2021;4:12(5):441.
23.Chevalier N, Vega A, Bouskine A, et al. Gpr30, thenon-classical membrane g protein related estrogenreceptor, is overexpressed in human seminoma andpromotes seminoma cell proliferation. PLoS One.2012;7(4):e34672.
24.Liu C, Liao Y, Fan S, et al. G-protein-coupledestrogen receptor antagonist g15 decreasesestrogen-induced development of non-small celllung cancer. Oncol Res. 2019;21:27(3):283-92.
25.Liu Y, Du FY, Chen W, et al. G15 sensitizesepithelial breast cancer cells to doxorubicin bypreventing epithelial-mesenchymal transitionthrough inhibition of GPR30. Am J Transl Res.2015;15:7(5):967-75.
26.Luo H, Yang G, Yu T, et al. GPER-mediatedproliferation and estradiol production in breastcancer-associated fibroblasts. Endocr Relat Cancer.2014;7:21(2):355-69.
27.Chen Y, Hong DY, Wang J, et al. Baicalein, unlike4-hydroxytamoxifen but similar to G15, suppresses17β-estradiol-induced cell invasion, and matrixmetalloproteinase-9 expression and activation inMCF-7 human breast cancer cells. Oncol Lett.2017;14(2):1823-30.
28.Compton DR, Sheng S, Carlson KE, et al.Pyrazolo[1,5-α]pyrimidines: Estrogen receptorligands possessing estrogen receptor β antagonistactivity. J Med Chem. 2004;18:47(24):5872-93.
29.Hsu I, Chuang KL, Slavin S, et al. Suppression ofERβ signaling via ERβ knockout or antagonistprotects against bladder cancer development.Carcinogenesis. 2014;35(3):651-61.
30. Jiang H, Fan J, Cheng L, Hu P, Liu R. The anticancer activity of genistein is increased in estrogenreceptor beta 1-positive breast cancer cells. OncoTargets Ther. 2018;14;11:8153-63.
31.Mendes C, Lopes-Coelho F, Ramos C, et al.Unraveling FATP1, regulated by ER-β, as a targetedbreast cancer innovative therapy. Sci Rep.2019;1;9(1):14107.
32.Al-Khyatt W, Tufarelli C, Khan R, Iftikhar SY.Selective oestrogen receptor antagonists inhibitoesophageal cancer cell proliferation in vitro. BMCCancer. 2018;1:18(1):121.
33.Chan KKL, Leung THY, Chan DW, et al. Targetingestrogen receptor subtypes (ERα and ERβ) withselective ER modulators in ovarian cancer. JEndocrinol. 2014;12;221(2):325-36.
34.Treeck O, Diepolder E, Skrzypczak M, Schüler-Toprak S, Ortmann O. Knockdown of estrogenreceptor β increases proliferation and affects thetranscriptome of endometrial adenocarcinoma cells.BMC Cancer. 2019;29:19(1):745.
35.Arıcan ÇD. The Relationship of MicrosatelliteInstability Genes With Tumor Stage and Differencein Endometrial Carcinomas. Dicle Med J. 2022;49(2):343-51.